Background illustration for clinical trials search

Glomerulonephritis Clinical Trials

Browse 135 glomerulonephritis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

for
Autoimmune Disorders, Systemic Sclerosis,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06434363

Phase 1, Phase 2, Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

for
IC-MPGN
Location: Boston MA, New York NY, Montreal, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 12 - 60

Code: NCT05755386

Phase 3, Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

for
Focal Segmental Glomerulosclerosis, Minimal Change Disease,
Location: New Hyde Park NY, Neptune City NJ, Hackensack NJ,
Sponsor: Travere Therapeutics, Inc.

Sex: All

Age: 1 - 17

Code: NCT05003986

Phase 2, Recruiting

taVNS for FRNS in Children

for
Nephrotic Syndrome in Children, Minimal Change Disease,
Location: New Hyde Park NY, Philadelphia PA
Sponsor: Northwell Health

Sex: All

Age: 3 - 17

Code: NCT05588063

Recruiting

AMPK-activation by Metformin in FSGS: AMP-FSGS

for
Focal Segmental Glomerulosclerosis
Location: New Haven CT, New York NY
Sponsor: Yale University

Sex: All

Age: 18 - 70+

Code: NCT06090227

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

for
SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19,
Location: Philadelphia PA
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 10 - 29

Code: NCT06839976

Phase 1, Phase 2, Recruiting

A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy

for
Glomerulonephritis, Membranous
Location: Doral FL, Miami FL, Pembroke Pines FL, Los Angeles CA
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT07851220

Phase 3, Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

for
Primary IgA Nephropathy
Location: New York NY
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT04557462

Phase 3, Recruiting

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

for
Focal Segmental Glomerulosclerosis
Location: Worcester MA, Valhalla NY, New Bern NC, Catonsville MD,
Sponsor: Akebia Therapeutics

Sex: All

Age: 18+

Code: NCT07268638

Phase 2, Recruiting

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

for
IgA Nephropathy, Lupus Nephritis (LN),
Location: Hollywood FL, Orangeburg SC, Lawrenceville GA
Sponsor: Akebia Therapeutics

Sex: All

Age: 16+

Code: NCT06419205

Phase 2, Recruiting

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

for
Lupus Nephritis
Location: Orchard Park NY
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06711887

Phase 3, Recruiting

Wellness & Workforce Solution for Lupus/Lupus Nephritis

for
Lupus Nephritis
Location: Atlanta GA
Sponsor: Morehouse School of Medicine

Sex: Female

Age: 18+

Code: NCT06217107

Recruiting

US Zamto-cel Autoimmune Diseases

for
Lupus Nephritis, Systemic Lupus Erythematosus,
Location: Milwaukee WI
Sponsor: Miltenyi Biomedicine GmbH

Sex: All

Age: 18+

Code: NCT06708845

Phase 1, Recruiting

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

for
Primary Membranous Nephropathy
Location: Houston TX
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT07571746

Phase 2, Recruiting

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

for
Nephritis, Lupus, Lupus Erythematosus, Systemic
Location: Miami FL, Miami Lakes FL, Doral FL, Kissimmee FL,
Sponsor: Viatris Innovation GmbH

Sex: All

Age: 18 - 70+

Code: NCT07201129

Phase 3, Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

for
Refractory Lupus Nephritis, Myasthaenia Gravis,
Location: Denver CO
Sponsor: Kyverna Therapeutics

Sex: All

Age: 18+

Code: NCT07403188

Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

for
Primary Immunoglobulin A Nephropathy (IgAN)
Location: Philadelphia PA, Gainesville FL, Aurora CO,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 2 - 18

Code: NCT06994845

Phase 3, Recruiting

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

for
FSGS
Location: New York NY, Chicago IL
Sponsor: Apellis Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07213960

Phase 2, Phase 3, Recruiting

Safety and Efficacy of ONT01 in Lupus

for
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III,
Location: New York NY
Sponsor: Hospital for Special Surgery, New York

Sex: All

Age: 18+

Code: NCT07107659

Early Phase 1, Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

for
Primary Membranous Nephropathy
Location: New York NY, Miami FL, Winter Park FL, Orlando FL,
Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All

Age: 18 - 70+

Code: NCT07204275

Phase 2, Phase 3, Recruiting

Glomerulonephritis is inflammation of the glomeruli, the tiny filters inside the kidneys, and it can quietly cause protein and blood in the urine for years before kidney function declines. It includes several different diseases, such as IgA nephropathy, the most common worldwide, and FSGS, which often affects younger adults. For a long time treatment was limited to blood pressure medicines and broad immune suppression. Recent years brought the first targeted treatments for some forms, and many more are now being tested to protect kidney function before damage becomes permanent.